Can 68Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis.

OBJECTIVE: This article aims to evaluate the diagnostic value of 68Gallium-PSMA positron emission tomography/computerized tomography (68Ga-PSMA PET/CT) for lymph node (LN) staging in patients with prostate cancer (PCa) by a meta-analysis of diagnostic tests.
METHODS: We systematically retrieved articles from Web of Science, EMBASE, Cochrane Database, PubMed. The time limit is from the creation of the database until June 2019, and Stata 15 was used for calculation and statistical analyses.
RESULTS: Sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR), diagnostic odds ratio (DOR) and 95% confidence intervals (CI) be used to evaluate the diagnostic value. A total of 10 studies were included in our meta-analysis, which included 701 individuals. The results of each consolidated summary are as follows: sensitivity of 0.84 (95% CI 0.55-0.95), specificity of 0.95 (95% CI 0.87-0.98), PLR and NLR was 17.19 (95% CI 6.27, 47.17) and 0.17 (95% CI 0.05-0.56), respectively. DOR of 100 (95% CI 18-545), AUC of 0.97 (95% CI 0.95-0.98).
CONCLUSION: Our study demonstrates that 68Ga-PSMA PET/CT has a high overall diagnostic value for LN staging in patients with moderate and high-risk PCa. But our conclusions still require a larger sample size, multi-center prospective randomized controlled trial to verify.

Introduction

Prostate cancer (PCa) is the second most common cancer and the fifth leading cause of cancer death in developed countries [1]. Although the clinical symptoms of early PCa are not obvious, pelvic lymph node (LN) and bone metastasis are also prone to occur [2]. About 15% of patients with medium and high-risk prostate cancer were found to have harbor lymph node invasion when performing pelvic lymph node dissection (PLND) during radical prostatectomy (RP) [3]. PLND is undoubtedly the most reliable way to determine whether there is LNI in PCa, but this method is both invasive and expensive [4]. And complications such as lymphocele, lymphedema are also headaches [5]. Before performing PLND, it is necessary to routinely use nomograms to predict the extent of lymph node invasion before surgery. According to these nomograms, patients with a serum prostate-specific antigen (PSA) of over 10 ng/mL, a Gleason score of over 6, or a stage T3 tumour (according to the Tumour, Nodes, and Metastases [TNM] staging system) defined by digital rectal examination (DRE), have a 5–65% risk of lymph node involvement [6-8]. According to the EAU guidelines, patients with moderate to high risk PCa who have an LN-positive estimated risk of more than 5% should undergo extend pelvic lymph node dissection (ePLND) [9]. Therefore, accurate assessment of LN staging before surgery is important for the operation and patient’s prognosis.

Presurgical computerized tomography (CT) scan or magnetic resonance imaging (MRI) is helpful for LN staging, but with limited accuracy [10]. Prostate-specific membrane antigen (PSMA) is a surface protein that is expressed in almost normal prostate tissues, and its expression level is higher in PCa tissues [11]. In recent years, PSMA has been introduced into positron emission tomography (PET) imaging [12], 68Gallium-PSMA positron emission tomography/computerized tomography (68Ga-PSMA PET/CT) has been proven to be better than ordinary imaging tests in detecting metastatic PCa [13]. Related studies have also shown that 68Ga-PSMA PET/CT is more sensitive for recurrent PCa with a low prostate-specific antigen (PSA) [14, 15].

Till now, some scholars have done some research on the accuracy of 68Ga-PSMA PET/CT to determine the lymph node staging of PCa preoperative, but it’s still unclear how its diagnostic value is. The diagnostic accuracy of 68Ga-PSMA PET/CT to determine lymph node staging of PCa preoperative remains unclear based on the current literature. The current study aims to establish the status of 68Ga-PSMA PET/CT in PCa's LN staging.

Methods

Literature search and eligibility criteria

A systematic search of the published literature using Web of Science, EMBASE, Cochrane Database, PubMed was performed. We have selected relevant literature from the creation of the database to June 2019. And used prostate cancer, Gallium, lymph node, positron emission tomography/computerized tomography, prostate-specific membrane antigen as the search terms and the search language was limited to English. We also searched for the relevant bibliography to avoid omissions.

The studies that were included in our research should meet the demands as follows: patients diagnosed with LN metastatic PCa using the gold standard pathological biopsy, studies with the diagnostic value of 68Ga-PSMA PET/CT reflected in the studies, and studies with sufficient data on true positive (TP), false positive (FP), false negative (FN), and true negative (TN). For duplicate articles, low-quality research, letters, reviews, case report, we analyze and exclude respectively. This process was assessed by two authors (PL and LJZ), independently.

Data extraction

We incorporate the following data from each article into the meta-analysis: author, publication year, study design, patient recruitment time, lymph node dissection, average patient age, preoperative PSA, patient population characteristics: high/medium risk. The PCa and health group was diagnosed as positive and negative by 68Ga-PSMA PET/CT to calculate the number of true positives, false positives, true negatives, and false negatives. Data extraction was performed by two authors (PL and LJZ) with any discrepancies resolved by a third author (WTQ).

Quality evaluation

The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to evaluate the quality of included studies [13]. Key domains are assessed to determine the risk of bias and applicability. Signalling questions are included to facilitate judgements, with the risk being low if all signaling answer for a domain is 'yes', and if the answer to any question is 'no' suggesting potential bias exists. Concerns about applicability are determined as 'low', 'high', or 'unclear'.

Statistical analysis

We used Stata 15 (StataCorp LP, University City, Texas, USA) for statistical analysis. Q test and chi-square tests were used to verify the heterogeneity between the included works of literature. If I2 > 50%, the differences between the literature were considered significant [16]. We used a bivariate model to calculate the pooled sensitivity, specificity, positive and negative likelihood ratios (PLRs and NLRs), diagnostic odds ratio (DOR) and the 95% confidence interval (CI) [17]. We calculated the area under the receiver operator characteristic curve (SROC, AUC). AUC varied from 0.5 to 1. If the area was equal to 1, then a diagnostic test was extremely valuable. If the area was 0.5, then the diagnostic ability was considered as poor [18]. Deeks’s funnel plot was used to assess the publication bias, and Fagan plots showed the relationship between the prior probability, the likelihood ratio, and the posterior test probability [19]. P < 0.05 was considered statistically significant.

Results

Study selection and study characteristics

The literature search selection steps retrieval in Fig. 1. Initially, we retrieved a total of 324 articles in the selected database and manually retrieved 22 articles by referring to relevant literature citations. In these studies, we excluded 134 duplicates records. By analyzing titles, abstracts, and topics, 142 articles were also excluded. Through full-text analysis and assessment of eligibility, 42 articles that were not related to diagnostic value, 12 articles that were no related to LN staging, and 6 studies that had no access data. Finally, we included 10 studies in our meta-analysis [2, 12, 13, 20–26].

Fig. 1

Flow diagram of studies selection process

In Table 1, we presented the basic data of the articles included in the meta-analysis of 68Ga-PSMA PET/CT for LN staging of PCa preoperative. These articles were published between 2016 and 2019. A total of 701 sample individuals were included in our analysis. Most of them are single-center retrospective studies in regions including Asia (China, India, and Turkey), Europe (Germany) and Australia. At the same time, we also display the age, PSA, patient characteristics and other information of patients included in each study.

Table 1

Characteristics of the included studies in the meta-analysis

References	Country	Study design	Study population	Recruiting time	Uptake time (min)	Lymphade-nectomy	Age Median (range) Median (IQRe)	PSAd median (range) Median (IQR)	Patient characteristics
Budaus [25]	Germany	Retrospective	Single center	June. 2014 to Mar. 2015	NA	ePLNDf	63 (44–75)	8.8 (1.4–376)	High risk
Herlemann [20]	Germany	Retrospective	Single center	Jan. 2014 to Aug. 2015	60	PLNDg	70.5 (59–80)b	56 (3.3–36.3)b	4 intermediate risk and 16 high risk
Maurer [24]	Germany	Retrospective	Single center	Dec. 2012 to Nov. 2014	59.8 ± 17.8a	PLND	66 (45–84)	11.6 (0.57–244)	42 intermediate risk and 88 high risk
Gupta [22]	India	Retrospective	Single center	Dec. 2014 to Dec. 2015	Nearly 60	ePLND	NA	NA	High risk
Obek [21]	Turkey	Retrospective	Single center	July. 2014 to Oct. 2015	45–60	ePLND	64 ± 6.0a	26.5 ± 21.4a	44 high risk and 7 very high risk
Van Leeuwen [26]	Australia	Prospective	Single center	Apr. to Oct. 2015	60	ePLND	65 (60–71)	65 (55–82)	3 intermediate risk and 27 high risk
Zhang [12]	China	Retrospective	Single center	Mar. to July. 2017	60	PLND	69 (55–82)	37.25 (7.2–348)	17 intermediate risk and 25 high risk
Van Leeuwen [2]	Australia	Retrospective	Single center	Feb. 2015 to Oct. 2017	60	ePLND	NA	9.4	140 intermediate risk and high risk
Yilmaz [23]	Turkey	Retrospective	Single center	May. 2016 to Apr. 2018	Approximately 60	rLNDc	62.8 (49–73)b	12 (2.4–32)b	15 intermediate risk and 6 high risk
Yaxley [13]	Australia	Retrospective	Single center	July. 2014 to Sep. 2017	45–60	PLND	68 (44–80)	7.6 (1.5–51)	85 intermediate risk and 123 high risk

aMean ± SD

bMean (range)

crLND, regional lymph node dissection

dPSA, prostate specific antigen

eIQR, interquartile range

fePLND, extend pelvic lymph node dissection

gPLND, pelvic lymph node dissection

Quality assessment

Based on the evaluation results of the QUADAS-2 scale, we reflected the quality evaluation results of each article in Table 2. The final score of each article was 11 or better, and 7 of them received quite high scores.

Table 2

Summary estimated of diagnostic performance of the 68Ga-PSMA PET/CT for lymph node staging in patient with Prostate Cancer

References	Sample size	TPa	FPb	FNc	TNd	Quality
Budaus [25]	30	33	0	67	100	11
Herlemann [20]	34	91	33	9	67	10
Maurer [24]	130	66	1	34	99	11
Gupta [22]	12	100	20	0	80	10
Obek [21]	51	53	14	47	86	10
Van Leeuwen [26]	30	64	5	62	94	11
Zhang [12]	42	93	4	7	96	9
Van Leeuwen [2]	140	60	12	40	88	10
Yilmaz [23]	24	38	6	62	94	10
Yaxley [13]	208	38	6	62	94	11
Pooled analysis	Inconsistency (I2) (95% CI)		99% (98–99)
	Sample Size		701
	SENe (95% CI)		0.84 (0.55, 0.95)
	SPEf (95% CI)		0.95 (0.87, 0.98)
	PLRg (95% CI)		17.2 (6.3, 47.2)
	NLRh (95% CI)		0.17 (0.05, 0.56)
	DORi (95% CI)		100 (18, 545)
	Youden Index		0.79

68Ga-PSMA PET/CT, 68Gallium-PSMA positron emission tomography/computerized tomography

aTP, true positive

bFP, false positive

cFN, false negative

dTN, true positive

eSEN, Sensitivity

fSPE, Specificity

gPLR, Positive Likelihood Ratio

hNLR, Negative Likelihood Ratio

iDOR, Diagnostic Odds Ratio

Pooled diagnostic values

After statistical tests, the value of I2 is greater than 50%, it can be considered that the included documents have high heterogeneity. Therefore, a random effect model is used to combine sensitivity and specificity, thereby obtaining more conservative results. The diagnostic value is shown in Table 2. The pooled sensitivity and specificity were recorded as 0.84 (95% CI 0.55–0.95) and 0.95 (95% CI 0.87–0.98, Fig. 2), respectively. The Youden index was 0.79. The pooled PLR and NLR was 17.19 (95% CI 6.27–47.17) and 0.17 (95% CI 0.05–0.56), and DOR of 100 (95% CI 18–545). The overall SORC curve is presented in Fig. 3, with an AUC of 0.97 (95% CI 0.95–0.98). Figure 4 is shown in the Fagan plot. The prior probability was 20%, and the post-test probability was 81% for LR-positive and 4% for LR-negative. The diagnostic accuracy for detecting 68Ga-PSMA PET/CT for LN staging in PCa was found to be generally better.

Fig. 2

Forest plot of pooled sensitivity and specificity of 68Ga-PSMA PET/CT for lymph node staging in patient with prostate cancer

Fig. 3

The SORC curve of 68Ga-PSMA PET/CT for lymph node staging in patient with prostate cancer

Fig. 4

Fagan diagram evaluating the overall diagnostic value of 68Ga-PSMA PET/CT for lymph node staging in patient with prostate cancer

Publication bias

The publication bias (P = 0.02, Fig. 5) was shown in Deek’s funnel plot.

Fig. 5

Deek’s funnel plot to evaluate the publication bias

Heterogeneity and sensitivity analysis

According to the results of the forest plot, the heterogeneity of 68Ga-PSMA PET/CT was high in both sensitivity (I2 = 97.25%) and specificity (I2 = 95.12%). Due to the small number of studies we included (n = 10) that prevented meta-regression from being implemented, a random-effects model was used to pool the data of 68Ga-PSMA PET/CT.

Meta regression and subgroup analysis

Meta-regression and subgroup analysis were performed on study design (predesign), gold standard selection and description (samemth and reftest), diagnostic test to be evaluated (index), and patient characteristics (subject). It can be seen from the forest plot that in the study we included, the five independent variables had no statistically significant effects on sensitivity and specificity (P > 0.05, Fig. 6).

Fig. 6

Meta regression and subgroup analysis

Discussion

Based on the currently published research, our meta-analysis fills the gap of 68Ga-PSMA PET/CT in the diagnosis of middle/high-risk prostate cancer lymph node staging to a certain extent. We found that the indicators and results of 68Ga-PSMA PET/CT show a satisfactory diagnostic efficacy.

In previous treatments, LN staging of prostate cancer patients can only be determined by performing PLND according to the situation during the operation. However, this method is not always feasible [27]. Clinically, the use of PLND is not always feasible, being restricted for the following reasons: not every patient will receive PLND, limited anatomical locations performed, and consideration regarding complications [28-30], resulting in suboptimal lymph node staging. 68Ga-PSMA PET/CT is a more accurate method to determine the LN stage of PCa patients before surgery [31], which can be incorporated into clinical practice. The common lymph node metastasis sites for prostate cancer are obturator lymph node, internal iliac lymph node, external iliac lymph node, common iliac lymph node, presacral lymph node, abdominal aortic lymph node and mediastinum, supraclavicular lymph node. Studies have shown that the most common lymph node metastasis sites for prostate cancer are external iliac lymph nodes and obturator lymph nodes, with the median percentages being 12.2% and 11.6%, respectively [32]. Based on the current evidence, the diagnostic performance of auxiliary imaging and nomograms tool for prostate cancer lymph node metastasis still has limitations, especially for lymph nodes < 5 mm. Preoperative assessment of the degree of lymph node metastasis can guide the selection of surgical procedures, which can further assist the management of patients after radical prostatectomy [33-35]. Therefore, it is particularly important to find a non-invasive and better diagnostic method.

Our meta-analysis included 10 studies from different countries and regions, involving a total of 701 patients. The pooled specificity of 0.95 (95% CI 0.87–0.98) for 68Ga-PSMA PET/CT. But pooled sensitivity was recorded as 0.84 (95% CI 0.55–0.95), which is not enough to convince us to give up the remaining 20% of the patient. The Youden index was 0.79. AUC was 0.97 (95% CI 0.95–0.98), which was in line with our initial predictions. Through these comprehensive indicators, we can think that 68Ga-PSMA PET/CT has better diagnostic efficacy in preoperative LN staging in patients with prostate cancer. In the past few decades, CT and MRI have been used to determine the LN staging before radical prostatectomy, but their accuracy rate is still low compared to the gold standard [9]. Hovels et al. Performed a meta-analysis of 24 studies to assess CT/MRI for preoperative evaluation of LN staging. In his research, for CT, pooled sensitivity and specificity was 0.42 (95% CI 0.26–0.56) and 0.82 (95% CI 0.8–0.83) respectively. For MRI, pooled sensitivity and specificity was 0.39 (95% CI 0.22–0.56) and 0.82 (95% CI 0.79–0.83) [36]. From this point of view, the performance of CT and MRI in judging LN staging is not satisfactory. If clinicians rely on CT or MRI, they will easily make the wrong decision on the patient’s condition. In our analysis, we could see that two studies have lower sensitivity, 0.38(95%: 0.28–0.48) and 0.33 (95% CI 0.24–0.43) respectively [13, 25]. The reason for this analysis was that, due to the technical level of the test, the sample size, and bias between the samples, it might have lead to different final results. The specificity value provided in one study is significantly lower [20]. We thought that the main reason is that the patients included in Herlemann’s [20] study received different PLNDs. Among them, 20 received primary PLND and 14 received secondary PLND, which may be the main reason for the lower specificity. Multi-parameter magnetic resonance (mpMR) also plays a large role in the preoperative evaluation of prostate cancer, especially in judging extraprostatic extension (EPE) of the tumor, invasion of the seminal vesicle (SVI) [23]. In a retrospective study by Van Leeuwen et al. They also compared the diagnostic accuracy of mpMR and 68Ga-PSMA PET/CT for LN metastasis in a patient with intermediate high-risk PCa. The sensitivity was 14% and 53%, respectively, and the specificity was 99% and 88%, respectively [2]. All of these indicated that 68Ga-PSMA PET/CT has better diagnostic efficacy and was expected to be popularized and used in clinical.

The higher the value of DOR, the better the diagnostic value of this diagnostic method. In our study, The DOR value was 100 (95% CI 18–545), indicating that the overall accuracy was high. Pooled PLR and NLR value was 17.19 (95% CI 6.27–47.17) and 0.17 (95% CI 0.05–0.56), respectively. This can be understood as the probability of 68Ga-PSMA PET/CT correctly judging LN metastasis is 17 times that of misjudging, and the probability of correctly judging LN non-metastasis is 0.17 times that of misjudging. At the same time, we also noticed that the publication bias shown by Deek’s funnel plot (Fig. 5) has a P-value of 0.02. It is understandable that most of the articles we included were retrospective trials, which led to the results. In addition, meta regression and subgroup analysis showed that there is no statistical difference between the above-mentioned influencing factors for the obtained sensitivity and specificity values, excluding the influence of other factors on the results. From the data results, it is worth trying to use 68Ga-PSMA PET/CT to diagnose LN staging in patients with PCa.

We perform this meta-analysis strictly according to PRISMA checklist [37]. However, there are still some limitations in our meta-analysis. First, most of the studies we included were single-center retrospective studies, and the existence of selection bias may affect our judgment. Second, the sample populations included in these articles are only Asia, Europe, and Australia, so population bias is unavoidable. Third, the sample size is too small. The current research is not registered, and there may be small deviations, but we still strictly follow the steps of systematic reviews. Due to the clinical application of 68Ga-PSMA PET/CT in the future, there is not a sufficiently large sample size to be included in our meta-analysis. Compared with PLND, although 68Ga-PSMA PET/CT has only moderate sensitivity and better specificity, it can perform relatively accurate LN staging of detected PCa patients. At this point, 68Ga-PSMA PET/CT is due to any other imaging examinations, but due to many limitations, our conclusions still require a larger sample size, multi-center prospective randomized controlled trial to verify.

Conclusion

Based on the current evidence, 68Ga-PSMA PET/CT is bound to have a strong performance in the diagnosis of medium/high-risk prostate cancer lymph node staging due to its relatively excellent diagnostic accuracy. However, in a short period of time in the future, limited by the capacity of different medical institutions and the development of regional economic levels, it will take some time to fully demonstrate its advantages in the field of prostate cancer. Further studies in 68Ga-PSMA PET/CT are needed, and efforts are warranted to improve understanding and intervention of these diagnostic deviations and effectiveness.